[ad_1] Novo Nordisk A/S is spending 15.9 billion Danish kroner ($2.29 billion) to expand production facilities in Denmark as the obesity drug manufacturer looks to ensure capacity for its future…
Tag: NOVO NORDISK A/S-B
Macron Finally Has Something to Brag About
[ad_1] Bonjour et bienvenue to the Paris Edition. I’m Paris Bureau Chief Alan Katz . If you haven’t yet, subscribe now to the Paris Edition newsletter . French President Emmanuel…
Ozempic Maker Novo Nordisk Invests $2.3 Billion in France Site
[ad_1] Novo Nordisk A/S plans to invest €2.1 billion ($2.3 billion) to expand production in France as it works to meet surging demand for its sought-after weight-loss medicines. The construction…
Danish Economy Slips Into Recession Amid Pharmaceutical Decline
[ad_1] Denmark probably slipped into a recession last quarter due to a significant decline in output by the Nordic country’s drugmakers. Danish gross domestic product dropped 0.3% in the third…
Danish Central Bank Raises GDP Forecasts Through 2025 on Pharma
[ad_1] The success of Novo Nordisk A/S and other Danish drugmakers abroad prompted the country’s central bank to raise its economic growth forecast through 2025. Gross domestic product will probably…
Novo’s Value Surpasses Denmark GDP After Obesity Drug Boost
[ad_1] Novo Nordisk A/S has just reached another milestone in its meteoric rise: the market value of the Danish company has exceeded the size of its domestic economy. The shares…
Denmark’s Economy Contracted in Second Quarter After Revision
[ad_1] Denmark’s economy contracted in the second quarter instead of expanding as initially reported, with the boon from its pharmaceutical industry falling short to offset a broad-based weakening. Gross domestic…
With Novo Nordisk, Denmark Wants to Avoid the Nokia Trap
[ad_1] Welcome to the weekend issue of Brussels Edition, Bloomberg’s daily briefing on what matters most in the heart of the European Union. Join us on Saturdays for deeper dives…
Obesity Drugs Enjoy a Much-Needed Winning Streak
[ad_1] Several critical advances this month will go a long way toward making obesity drugs more widely available to patients: more consistent access, improved affordability and global conviction that these…
Novo Nordisk’s Growth Camouflages Weak Spots in Danish Economy
[ad_1] The massive growth of Novo Nordisk A/S is concealing weaknesses in Denmark’s economy, which would have stagnated over the past year and a half without its pharmaceutical industry. Drugmakers…